Total amount: € 0,00
Certan D. 1, Righini V. 1, Oliva M. 2, Bevilacqua M. 1
1 SSD Endocrinologia e Diabetologia, Azienda Ospedaliera Luigi Sacco, Milano, Italia;
2 Società Italo Britannica L. Manetti H. Roberts & C., Calenzano, Firenze, Italia
Aim: The aim of the present study was to assess the systemic effects of a cycle of treatment with a topical formulation of l-T4 and escin (Somatoline®) in healthy women based on changes in bioavailability of FT4, FT3, rT3, and TSH.
Methods: This study enrolled 20 healthy adult women with Body Mass Index (BMI) <30, not exposed to iodine-containing products. The study required 28 consecutive days of treatment with Somatoline® followed by a 14-day follow-up period. Blood samples for FT4, FT3 and TSH levels were drawn at baseline, 5 and 24 hours after the first application and thereafter on days 14, 28 and 42. Levels of rT3 were measured during the first 24 hours postapplication.
Results: Subjects’ mean age was 40.1±8 years and BMI from 19.1 to 29.8. Levels of FT4 always remained within normal range and did not change in a clinically relevant way from baseline (11±1.2 pg/dl), with maximum mean change from pretreatment values of 0.4 pg/ml (P=0.87). Likewise, FT3 and TSH levels did not change significantly from baseline (3±0.4 pg/dl and 1.8±0.9 EU/ml, respectively). Levels of rT3 behaved in a similar way, with modest changes from baseline (P=0.29). Local tolerability was defined “excellent” for 19 out of 20 women (95%) and “moderate” in one subject who experienced the onset of folliculitis, for which causal correlation with the treatment was considered “possible”.
Conclusion: Used at the posology foreseen for the marketed formulation, Somatoline® does not affect plasma levels of FT4, FT3, rT3 and TSH, either in the short or in the long-term.